Emma Reeve Sells 10,000 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) Director Emma Reeve sold 10,000 shares of PTC Therapeutics stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $79.50, for a total value of $795,000.00. Following the transaction, the director owned 6,666 shares in the company, valued at approximately $529,947. The trade was a 60.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Emma Reeve also recently made the following trade(s):

• On Wednesday, November 12th, Emma Reeve sold 7,333 shares of PTC Therapeutics stock. The stock was sold at an average price of $74.50, for a total value of $546,308.50.
• On Thursday, October 30th, Emma Reeve sold 15,666 shares of PTC Therapeutics stock. The shares were sold at an average price of $69.50, for a total transaction of $1,088,787.00.
• On Friday, October 3rd, Emma Reeve sold 25,562 shares of PTC Therapeutics stock. The shares were sold at an average price of $65.96, for a total transaction of $1,686,069.52.
• On Thursday, September 11th, Emma Reeve sold 15,705 shares of PTC Therapeutics stock. The stock was sold at an average price of $59.50, for a total transaction of $934,447.50.

PTC Therapeutics Price Performance

NASDAQ:PTCT opened at $86.25 on Thursday. The company’s 50-day moving average is $68.42 and its two-hundred day moving average is $56.44. PTC Therapeutics, Inc. has a 1-year low of $35.95 and a 1-year high of $87.50. The firm has a market capitalization of $6.92 billion, a price-to-earnings ratio of 12.37 and a beta of 0.60.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.19) by $1.39. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. The business had revenue of $211.01 million during the quarter, compared to the consensus estimate of $177.42 million. During the same quarter last year, the firm earned ($1.39) EPS. The business’s revenue was up 7.2% compared to the same quarter last year. PTC Therapeutics has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PTCT. CIBC Bancorp USA Inc. purchased a new stake in PTC Therapeutics during the 3rd quarter worth approximately $508,000. Danske Bank A S acquired a new position in shares of PTC Therapeutics in the third quarter worth $1,152,000. CANADA LIFE ASSURANCE Co increased its position in shares of PTC Therapeutics by 55.9% during the third quarter. CANADA LIFE ASSURANCE Co now owns 33,984 shares of the biopharmaceutical company’s stock worth $2,060,000 after acquiring an additional 12,191 shares during the period. Woodline Partners LP acquired a new stake in shares of PTC Therapeutics in the third quarter valued at $6,481,000. Finally, Qube Research & Technologies Ltd boosted its holdings in PTC Therapeutics by 27.4% in the third quarter. Qube Research & Technologies Ltd now owns 430,934 shares of the biopharmaceutical company’s stock valued at $26,446,000 after purchasing an additional 92,771 shares during the period.

Analyst Ratings Changes

Several brokerages have recently commented on PTCT. TD Cowen upped their price target on PTC Therapeutics from $50.00 to $63.00 and gave the company a “hold” rating in a research note on Wednesday, November 5th. Bank of America lowered their target price on shares of PTC Therapeutics from $82.00 to $76.00 and set a “buy” rating for the company in a research note on Wednesday, August 20th. Cantor Fitzgerald reiterated an “overweight” rating and set a $118.00 price target on shares of PTC Therapeutics in a research report on Wednesday, September 3rd. Wall Street Zen upgraded shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of PTC Therapeutics in a research report on Tuesday. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, PTC Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $75.40.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.